Purchase Order 75N91019P00432

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $12,098.14 on May 5, 2021, for custom gene synthesis, custom peptide synthesis, direct cloning, plasmid preparation, and crude peptide library services. The order carries no small business set-aside. Work is performed in Piscataway, New Jersey, with an ultimate completion date of June 15, 2021.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,663.10 on May 28, 2019, to procure custom gene synthesis, custom peptide synthesis, direct cloning, and plasmid services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of June 27, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,666.96 on June 28, 2017. Performance occurs in Piscataway, New Jersey. The order procures peptide services on a firm fixed price basis, with ultimate completion targeted for July 27, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,484.18 on August 12, 2019, for sequencing services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and is scheduled for completion by September 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,567.96 on August 11, 2017, for peptide services. Work is performed at the awardee's facility in Piscataway, New Jersey. The order is firm fixed price and carries a completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $3,964.20 on September 5, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price structure and ultimate completion date of October 5, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to GenScript USA Inc. for $6,126.56 on July 28, 2017, for sequencing services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $6,230.90 on April 2, 2018, with an ultimate completion date of May 3, 2018. No set-aside category was used. Place of performance is Piscataway, New Jersey. The order carries firm fixed price pricing for biotechnology and molecular biology services, consistent with Genscript's core offerings in gene synthesis, protein production, and antibody development for federal research institutions.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $12,823.88 on July 24, 2019. The order covers sequencing services at the awardee's location in Piscataway, New Jersey, with an ultimate completion date of August 23, 2019. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services on August 17, 2017, with a ceiling value of $8,353.96 and an ultimate completion date of September 30, 2017. Work is performed in Piscataway, New Jersey. The order is a firm fixed price purchase order with no set-aside.</p>